Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Richard J. Barohn
Sign up to set email alerts
336
Publications
9,878
Citation Statements Received
6,029
Citation Statements Given
How they've been cited
15,488
300
9,531
47
How they cite others
7,564
117
5,889
23
Affiliations
University of Kansas Medical Center
,
University of Missouri
Publications
Order By: Most citations
Mutations in Kir2.1 Cause the Developmental and Episodic Electrical Phenotypes of Andersen's Syndrome
Plaster
1
,
Tawil
2
,
Tristani‐Firouzi
3
et al.
2001
Cell
Abstract
Show
995
13
792
1
Get access via publisher
Add to collection
Cite
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
Howard
1
,
Utsugisawa
2
,
Benatar
3
et al.
2017
The Lancet Neurology
868
38
676
4
5
Get access via publisher
Add to collection
Cite
Myasthenia gravis
Jaretzki
1
,
Barohn
2
,
Ernstoff
3
et al.
2000
Neurology
1,671
8
700
3
Get access via publisher
Add to collection
Cite
Randomized Trial of Thymectomy in Myasthenia Gravis
Wolfe
1
,
Kaminski
2
,
Aban
3
et al.
2016
N Engl J Med
Abstract
Show
978
18
613
5
11
Get access via publisher
Add to collection
Cite
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
Howard
1
,
Bril
2
,
Vu
3
et al.
2021
The Lancet Neurology
750
45
556
3
3
Get access via publisher
Add to collection
Cite
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
Nicolas
1
,
Kenna
2
,
Renton
3
et al.
2018
Neuron
Abstract
Show
758
13
497
0
Get access via publisher
Add to collection
Cite
Myasthenia gravis activities of daily living profile
Wolfe
1
,
Herbelin
2
,
Nations
3
et al.
1999
Neurology
Abstract
Show
584
1
443
3
Get access via publisher
Add to collection
Cite
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
Muppidi
1
,
Utsugisawa
2
,
Benatar
3
et al.
2019
Muscle and Nerve
Abstract
Show
264
27
266
1
Get access via publisher
Add to collection
Cite
1
2
3
4